Therapeutic agents and corresponding treatments
View Patent ↗Compositions and methods of using an MT103 family member, wherein MT103 is the chemical N,N-dicyclohexyl-(1S)-isoborneol-10-sulfonamide. Uses of the compositions include cancer therapy, antibacterials, antifungals, induction of apoptosis, and hormonal antagonists.
1. A pharmaceutical composition comprising a unit dosage form comprising a pharmaceutically acceptable carrier or diluent containing a therapeutically effective amount for treatment of cancer in a patient of a chemical having the formula:
wherein R 1 , R 2 , R 3 , R 4 , and R 5 are independently chosen from the group consisting of H, OH, C 1 -C 3 alkyl, a halogen, primary amine, secondary amine, tertiary amine, carboxy, alkoxy, alkyoxycarbonyl, carboxamido, and C 1 -C 3 alkenyl;
wherein R 6 and R 7 are independently chosen from the group consisting of H, C 1 -C 3 alkyl, and C 1 -C 3 alkenyl; and,
wherein R 8 , and R 9 are independently chosen from the group consisting of chemical groups having 1 to 12 carbons;
or a pharmaceutically acceptable salt thereof.
2. The composition of claim 1 wherein R 8 and R 9 are independently chosen from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkenyl, and C 6 cycloalkyls derivitized with at least one member of the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkenyl, hydroxyl, and carboxyl.
3. The composition of claim 2 wherein at least one of R 8 and R 9 is C 3 alkyl.
4. The composition of claim 2 wherein at least one of R 8 and R 9 is methyl.
5. The composition of claim 2 wherein at least one of R 8 and R 9 is C 6 cycloalkyl and at least one of R 8 and R 9 is C 6 cycloalkyl derivitized with at least two methyls.
6. The composition of claim 2 wherein at least one R 8 and R 9 is C 6 cycloalkyl derivitized with at least two C 1 -C 2 alkenyls and at least one of R 6 and R 7 is C 1 -C 2 alkyl.
7. The composition of claim 6 wherein at least one of R 8 and R 9 is C 6 cycloalkyl.
8. The composition of claim 2 wherein at least one of R 8 and R 9 is C 6 cycloalkyl derivitized with at least one member of the group consisting of C 1 -C 3 alkyl and carboxyl.
9. The composition of claim 8 wherein at least one of R 8 and R 9 is C 6 cycloalkyl and at least one of R 6 and R 7 is C 1 -C 2 alkyl.
10. The composition of claim 2 wherein at least one of R 8 and R 9 is C 6 cycloalkyl derivitized with at least one hydroxyl.
11. The composition of claim 10 wherein at least one of R 8 and R 9 is C 6 cycloalkyl and at least one of R 6 and R 7 is C 1 -C 2 alkyl.
12. The composition of claim 2 wherein and R 8 R 9 are independently chosen from the group consisting of C 6 cycloalkyl and C 6 cycloalkyls derivitized with at least one member of the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkenyl, hydroxyl, and carboxyl.
13. The composition of claim 12 wherein R 6 and R 7 are independently chosen from the group consisting of H and methyl.
14. A composition for administration to a cell, the composition comprising a unit dosage form comprising at least one therapeutic chemical in a pharmaceutically acceptable carrier, the therapeutic chemical having the formula:
wherein R 1 , R 2 , R 3 , R 4 , and R 5 are independently chosen from the group consisting of H, OH, C 1 -C 3 alkyl, a halogen, primary amine, secondary amine, tertiary amine, carboxy, alkoxy, alkyoxycarbonyl, carboxamido, and C 1 -C 3 alkenyl;
wherein R 6 and R 7 are independently chosen from the group consisting of H, C 1 -C 3 alkyl, and C 1 -C 3 alkenyl; and
wherein R 8 and R 9 are independently chosen from the group consisting of chemical groups having 1to 12 carbons;
or a pharmaceutically acceptable salt thereof.
15. The composition of claim 14 wherein the at least one chemical is chosen from the group consisting of N,N-dicyclohexyl-(1S)-isoborneol-10-sulfonamide, N,N-diisopropyl2-hydroxy-7,7-dimethylbicyclo[2.2.1]hept-1-ylmethanesulfonamide, N,N-dimethyl-2-hydroxy-7,7-dimethylbicyclo[2.2.1]hept-1-ylmethanesulfonamide, N-cyclohexyl-N-(3,4-dimethylcyclohexyl)-2,3-dihydroxy-7,7-dimethylbicyclo[2.2.1]hept-1-ylmethanesulfonamide, N1-cyclohexyl-N]-{4-[(E)ethylidone]-3-methylenecycolhexyl}-1-(2-hydroxy-7,7-dimethylbicyclo[2.2.1]hept-1-yl)-1-ethylenesulfonamid; 4-cyclohexyl[(1-(2-hydroxy-7,7-dimethylbicyclo[2.2.1]hept-1-yl)vinyl]sulfanamido-2-methyl-1,3-cyclohexanedicaxboxylic acid, 4-[3,4-dihydroxycyclohexyl(2-hydroxy-7,7-dimethylbicyclo[2.2.1]hept-1-ylmethyl)sulfonamido]-2-methyl-1,3-cyclohexanedicarboxylic acid, and stereoisomers thereof.
16. The composition of claim 14 wherein the composition further comprises a second chemical having an anti-cancer activity upon exposure to the cell.
17. The composition of claim 14 wherein the composition further comprises a second chemical having apoptotic activity upon exposure to the cell.
18. The composition of claim 14 wherein the composition further comprises a second chemical that can act as an antagonist for hormones upon exposure to the cell.
19. The composition of claim 14 wherein the composition further comprises a second chemical having hypolipidemic activity upon exposure to the cell.
20. The composition of claim 14 wherein the composition further comprises a second chemical having antibacterial or antifungal activity upon exposure to the cell.
21. The composition of claim 1 wherein the pharmaceutically acceptable carrier or diluent comprises a binder, lubricant, disintegrating agent, coloring agent, flavoring agent, flow-inducing agent, melting agent, or a combination thereof.
22. The composition of claim 1 wherein the pharmaceutically acceptable carrier or diluent is a solid.
23. The composition of claim 22 wherein the composition is in a form of a capsule, tablet, or powder.
24. The composition of claim 1 wherein the composition is in a form for oral, rectal, topical, intravenous injection, or parenteral administration.
25. The composition of claim 1 wherein the pharmaceutically acceptable carrier or diluent is a liquid dosage form.
26. The composition of claim 25 wherein the composition is in a form of an elixir or syrup.
27. The composition of claim 14 wherein the pharmaceutically acceptable carrier or diluent comprises a binder, lubricant, disintegrating agent, coloring agent, flavoring agent, flow-inducing agent, melting agent, or a combination thereof.
28. The composition of claim 14 wherein the pharmaceutically acceptable carrier or diluent is a solid.
29. The composition of claim 28 wherein the composition is in a form of a capsule, tablet, or powder.
30. The composition of claim 14 wherein the composition is in a form for oral, rectal, topical, intravenous injection, or parenteral administration.
31. The composition of claim 14 wherein the pharmaceutically acceptable carrier or diluent is a liquid dosage form.
32. The composition of claim 31 wherein the composition is in a form of an elixir or syrup.
33. The composition of claim 14 wherein R 8 and R 9 are independently chosen from the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkenyl, C 3 -C 6 cycloalkyl, C 3 -C 6 cycloalkenyl, and C 6 cycloalkyls derivitized with at least one member of the group comprising of C 1 -C 4 alkyl, C 1 -C 4 alkenyl, hydroxyl, and carboxyl.
34. The composition of claim 33 wherein at least one of R 8 and R 9 is C 3 alkyl.
35. The composition of claim 14 wherein at least one of R 8 and R 9 is methyl.
36. The composition of claim 14 wherein at least one of R 8 and R 9 is C 6 cycloalkyl and at least one of R 8 and R 9 is C 6 cycloalkyl derivitized with at least two methyls.
37. The composition of claim 14 wherein at least one of R 8 and R 9 is C 6 cycloalkyl derivitized with at least two C 1 -C 2 alkenyls and at least one of R 6 , and R 7 is C 1 -C 2 alkyl.
38. The composition of claim 14 wherein at least one of R 8 and R 9 is C 6 cycloalkyl.
39. The composition of claim 14 wherein at least one of R 8 and R 9 is C 6 cycloalkyl derivitized with at least one member of the group consisting of C 1 -C 3 alkyl and carboxyl.
40. The composition of claim 14 wherein at least one of R 8 and R 9 is C 6 cycloalkyl and at least one of R 6 and R 7 is C 1 -C 2 alkyl.
41. The composition of claim 14 wherein at least one of R 8 and R 9 is C 6 cycloalkyl derivitized with at least one hydroxyl.
42. The composition of claim 14 wherein at least one of R 8 and R 9 is C 6 cycloalkyl and at least one of R 6 and R 7 is C 1 -C 2 alkyl.
43. The composition of claim 14 wherein R 8 and R 9 are independently chosen from the group consisting of C 6 cycloalkyl and C 6 cycloalkyls derivitized with at least one member of the group consisting of C 1 -C 4 alkyl, C 1 -C 4 alkenyl, hydroxyl, and carboxyl.
44. The composition of claim 43 wherein R 6 and R 7 are independently chosen from the group consisting of H and methyl.